The Canada Cell Analysis Market was valued at $942.76 Million in 2023 and projected to reach to $1528.17 Million by 2028, representing a compound annual growth rate of 10.1%. Canada's cell analysis market is positioned for sustained growth through 2028, driven by increasing adoption of advanced diagnostic technologies and cell-based therapeutic development.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada's cell analysis market reached $942.76 million in 2023 and is projected to grow to $1,528.17 million by 2028, representing a robust 10.1% CAGR, outpacing many developed markets in the region.
Canada's strengthening healthcare infrastructure and increased government funding for advanced diagnostic technologies are accelerating adoption of cell analysis solutions across research institutions and clinical laboratories.
Rising demand for cell-based therapies and regenerative medicine applications in Canada is driving significant investment in cell analysis platforms, particularly in oncology and immunotherapy research.
Canada's growing focus on personalized medicine and precision diagnostics is creating new opportunities for cell analysis technologies in genomics research and patient stratification applications.
| Report Metric | Details |
|---|---|
| Base Year | 2023 |
| Fastest Growing Segment | SINGLE-CELL ANALYSIS (Process) |
| Forecast Period | 2023–2028 |
| Growth Rate | CAGR of 10.9% from 2023 to 2028 |
| Largest Segment | REAGENTS & CONSUMABLES (Product & Service) |
| Market Size Base Year (Billions) | ~USD 20.21 (2023) |
| Revenue Forecast (Billions) | ~USD 33.9 (2028) |
| Segments Covered | Product & Service, Technique, Process, End User |
4 segment dimensions are covered across the global market.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC AND RESEARCH INSTITUTES | 134.91 | 153.74 | 166 | 180.21 | 197.06 | 217.01 | 240.7 | 269.08 | 10.1 |
| HOSPITALS AND CLINICAL TESTING LABORATORIES | 172.32 | 196.82 | 212.89 | 231.52 | 253.61 | 279.79 | 310.86 | 348.14 | 10.3 |
| OTHER END USERS | 192 | 219.07 | 236.82 | 257.4 | 281.79 | 310.7 | 345.02 | 386.17 | 10.3 |
| PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES | 266.93 | 303.5 | 327.05 | 354.33 | 386.65 | 424.95 | 470.37 | 524.78 | 9.9 |
| TOTAL | 766.16 | 873.13 | 942.76 | 1023.47 | 1119.11 | 1232.46 | 1366.94 | 1528.17 | 10.1 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug product services (finished dosage manufacturing & packaging),Pharmaceutical development services (formulation & clinical supply),Drug substance services (API & biologics), |
| ABCAM PLC | United Kingdom | Private Company | Primary and secondary antibodies,Conjugated antibodies and conjugation kits,Singleplex immunoassays, |
| BRUKER CORPORATION | United States | Public Company | BSI BioSpin (NMR/EPR and preclinical imaging),BSI CALID (mass spectrometry and diagnostics),BSI Nano (X-ray, AFM, microscopy, nano-metrology), |
| WAFERGEN BIO-SYSTEMS | United States | Private Company | SmartChip Real-Time PCR and Target Enrichment Systems,SmartChip Single-Cell Isolation System,Apollo 324 Library Preparation System and Reagents, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| DANAHER | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (instruments, genomics, and analytical systems),Diagnostics (clinical instruments and consumables), |
| GENERAL ELECTRIC | United States | Public Company | Commercial Engines & Services,Defense & Propulsion Technologies,Additive, Components & Other Systems, |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, bioprocessing, CDMO),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, equipment), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research and Bioprocess, |
| STANDARD BIOTOOLS | United States | Public Company | Proteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and legacy systems),Services, software, and other, |
| OLYMPUS CORPORATION | Japan | Public Company | Gastrointestinal Solutions (endoscopes, devices, services),Urology (visualization, stone management, BPH, bladder cancer),Respiratory (bronchoscopy, lung cancer, COPD), |
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology services sector.
Abcam PLC is a United Kingdom-based private company founded in 1998 with 1,760 employees providing research reagents and tools for the life sciences industry.
Bruker Corporation is a publicly traded U.S. company founded in 1960 with 11,085 employees manufacturing scientific instruments and analytical solutions.
WaferGen Bio-Systems is a U.S. private company founded in 2002 with 56 employees developing microfluidic and genomic analysis technologies.
Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees serving the life sciences, analytical, and diagnostics markets.
Danaher is a publicly traded U.S. company founded in 1969 with 59,000 employees operating across diversified industrial and life sciences sectors.
General Electric is a publicly traded U.S. company founded in 1892 with 57,000 employees operating across industrial, power, and healthcare sectors.
Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees engaged in pharmaceuticals, life sciences, and performance materials.
Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.
Bio-Rad Laboratories, Inc. is a publicly traded U.S. company founded in 1952 with 7,450 employees manufacturing clinical diagnostics and life science research products.
Standard Biotools is a publicly traded U.S. company founded in 1999 with 387 employees developing microfluidic and genomic analysis platforms.
Olympus Corporation is a publicly traded Japanese company founded in 1919 with 28,138 employees manufacturing optical and digital precision instruments.
Canada's cell analysis market was valued at $942.76 million in 2023 and is projected to reach $1,528.17 million by 2028.
Canada's cell analysis market is expected to grow at a compound annual growth rate (CAGR) of 10.1% from 2023 to 2028.
Key drivers include rising demand for cell-based therapies, personalized medicine initiatives, government support for biomedical research, and increased laboratory automation across Canadian healthcare institutions.
Flow cytometry, cell imaging systems, and automated cell counting technologies are experiencing significant adoption across Canadian research centers, hospitals, and commercial laboratories.
Canada represents a key growth market within North America, driven by its established life sciences ecosystem, regulatory support, and emphasis on precision and regenerative medicine research.
This study involved four major activities in estimating the current size of the cell analysis market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell analysis market. The secondary sources used for this study include World Health Organization (WHO), Organisation for Economic Co-operation and Development (OECD), International Society for Advancement of Cytometry (ISAC), International Society for Stem Cell Research (ISSCR), International Agency for Research on Cancer (IARC), Centers for Disease Control and Prevention (CDC), Society for Laboratory Automation and Screening (SLAS), Centers for Medicare & Medicaid Services (CMS), National Cancer Institute (NCI), European Commission (EC), American Society for Cell Biology (ASCB), European Society for Toxicology In Vitro (ESTIV), European Federation of Pharmaceutical Industries and Associations (EFPIA), Japan Society for Cell Biology (JSCB), Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Indian Society of Cell Biology (ISCB), Food and Drug Administration (FDA), Society of Biomolecular Imaging and Informatics (SBI2), Annual Reports, SEC Filings, Investor Presentations, Press Releases, Conferences, Journals, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

*Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue. As of 2021, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell analysis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Cell analysis is a technique used to study groups of cells and individual cells based on multiple parameters. It is used to measure cell properties such as size, shape, presence of specific proteins, proliferation, growth, morphology, porosity, and complexity.
Cell analysis products are used in various processes, which include cell identification, cell viability, cell proliferation, cell structure study, cell signaling pathway/signal transduction, cell counting & quality control, target identification & validation, cell interaction, and single-cell analysis. These processes are carried out by various end users such as hospitals & clinical testing laboratories, academic and research institutes, pharmaceutical & biotechnology companies, and other end users (CROs, cell culture collection repositories, food & beverage manufacturers, environmental monitoring organizations, forensic laboratories, and blood banks).
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Cell Analysis Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report